Cellectis (CLLS) Capital Expenditures (2015 - 2026)
Cellectis (CLLS) posted quarterly Capital Expenditures of -$265000.0 for Q1 2026, up 32.91% year-over-year from -$199381.0 in Q1 2025, and down 106.25% quarter-over-quarter from $4.2 million in Q4 2025.
Cellectis (CLLS) Capital Expenditures (2015 - 2026) Analysis & Trends
Cellectis' Capital Expenditures history runs 12 years deep, the most recent figure standing at -$265000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 32.91% year-over-year to -$265000.0; the TTM figure through Mar 2026 stood at $2.5 million (up 3.49% YoY), while the FY2025 annual figure was $2.4 million, down 8.63% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$265000.0, down from $4.2 million in the prior quarter.
- The five-year high for Capital Expenditures was $4.6 million in Q4 2024, with the low at -$1.2 million in Q3 2025.
- The 5-year median for Capital Expenditures is -$305000.0 (2025), against an average of $481294.1.
- Peak annual rise in Capital Expenditures reached 146.84% in 2024, while the deepest fall reached 284.44% in 2024.
- Cellectis' Capital Expenditures stood at $4.4 million in 2022, then tumbled by 57.69% to $1.9 million in 2023, then surged by 146.84% to $4.6 million in 2024, then retreated by 8.12% to $4.2 million in 2025, then slumped by 106.25% to -$265000.0 in 2026.
- Business Quant data shows CLLS's Capital Expenditures at -$265000.0 in Q1 2026, $4.2 million in Q4 2025, and -$1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -265,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -265,000.00 |
| Mar 31, 2026 | -265,000.00 |
| Dec 31, 2025 | 4.24 Mn |
| Dec 31, 2025 | 4.24 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | -305,000.00 |
| Jun 30, 2025 | -305,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | 4.62 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | -777,000.00 |
| Sep 30, 2024 | -777,000.00 |
| Jun 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Mar 31, 2024 | -218,000.00 |
| Mar 31, 2024 | -218,000.00 |
| Dec 31, 2023 | 1.87 Mn |
| Dec 31, 2023 | 1.87 Mn |